References
Caballer B, Finer N, Wurtman R. Plasma amino acid levels in obesity: effects of insulin resistance in amino acids in health and disease. New Perspectives: 369–382, 1987
Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, et-al. International trial of long term dexfenfluramine in obesity. Lancet 2: 1142–1145, 1989
Kirby MJ, Turner P. Do ‘anorectic’ drugs produce weight loss by appetite suppression? Lancet 1: 566–567, 1976
Lieberman HR, Wurtman JJ, Chew B. Changes in mood after carbohydrate consumption among obese individuals. American Journal of Clinical Nutrition 44(Suppl. 6): 772–778, 1986
O’Rourke D, Wurtman JJ, Wurtman R, Chebli R, Gleason R. Treatment of seasonal depression with d-fenfluramine. Journal of Clinical Psychiatry 50: 343–347, 1989
Silverstone T, Kyriakides M. Clinical pharmacology of appetite. In Silverstone T (Ed.) Drugs and appetite, pp. 93–123, Academic Press, London, 1982
Turner P. Dextrofenfluramine and the control of body weight: an overview. In Vague J et al. (Eds) Metabolic complications of human obesities, pp. 181–184, Exerpta Medica, Amsterdam, 1985
Turner P. Human implications of animal experiments — lessons from dexfenfluramine. Clinical Neuropharmacology 11(Suppl. 1): S113–S120, 1988
Turner P, Bichi LA, Slusarczyk H, Franklin CS. The peripheral actions of anti-obesity drugs. International Journal of Obesity 6: 411–415, 1982
Rights and permissions
About this article
Cite this article
Round-Table Discussion. Drugs 39 (Suppl 3), 63–66 (1990). https://doi.org/10.2165/00003495-199000393-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000393-00008